Two new drugs for obesity are getting close to approval
Two new drugs for obesity are getting close to approval...sibutramine (Meridia, Knoll) and orlistat (Xenical, Roche).
Sibutramine is a serotonin AND norepinephrine reuptake inhibitor. It's similar to the antidepressant Effexor (venlafaxine).
Sibutramine reduces appetite and increases metabolism...but it can also raise blood pressure.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote